<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/">
  <channel>
    <title>Drug coated balloon</title>
    <description>
      <![CDATA[]]>
    </description>
    <link>https://www.bioworld.com/rss</link>
    <language>en-us</language>
    <item>
      <title>SCAAR data Prevails for Medtronic paclitaxel-coated balloon</title>
      <author>holland.johnson@clarivate.com</author>
      <description>
        <![CDATA[Medtronic plc reported results from a registry highlighting the effectiveness of the Prevail paclitaxel-coated balloon. The findings from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR) were presented by Sacharias von Koch of the department of cardiology and clinical sciences at Lund University, Skåne University Hospital in Sweden at the Cardiovascular Research Technologies 2025 meeting in Washington. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/717877</guid>
      <pubDate>Tue, 11 Mar 2025 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/717877-scaar-data-prevails-for-medtronic-paclitaxel-coated-balloon</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2025/medtronic-prevail-11mar25.webp?t=1741727450" type="image/jpeg" medium="image" fileSize="119657">
        <media:title type="plain">Medtronic Prevail</media:title>
        <media:description type="plain">Medtronic Prevail paclitaxel-coated balloon. Credit: Courtesy Medtronic</media:description>
      </media:content>
    </item>
    <item>
      <title>Sirolimus gaining ground on paclitaxel for peripheral artery use</title>
      <description>
        <![CDATA[The contest between the two main classes of antiproliferatives for circulatory system use continues as seen in a presentation at this year’s Transcatheter Cardiovascular Therapeutics.]]>
      </description>
      <guid>http://www.bioworld.com/articles/713752</guid>
      <pubDate>Wed, 30 Oct 2024 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/713752-sirolimus-gaining-ground-on-paclitaxel-for-peripheral-artery-use</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Devices/cardiovascular-stent-drug-eluting-device.webp?t=1623790472" type="image/png" medium="image" fileSize="1574468">
        <media:title type="plain">Illustration of stent angioplasty balloon in artery</media:title>
      </media:content>
    </item>
    <item>
      <title>Paclitaxel shows well again in PAD via Chocolate Touch device</title>
      <description>
        <![CDATA[The days when paclitaxel was the subject of controversy in connection with peripheral artery disease (PAD) seem to be drawing to a close, thanks in part to a new drug-coated balloon (DCB) by Trireme Medical Inc., of Pleasanton, Calif. Trireme’s Chocolate Touch device, a second-generation DCB with paclitaxel as an antiproliferative, fared well against a legacy paclitaxel device, thus opening a new front in the competition in the PAD space and seemingly relieving any concerns about the safety of paclitaxel.]]>
      </description>
      <guid>http://www.bioworld.com/articles/518165</guid>
      <pubDate>Fri, 22 Apr 2022 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/518165-paclitaxel-shows-well-again-in-pad-via-chocolate-touch-device</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cardiovascular/PAD-artery-plaque.webp?t=1588379965" type="image/png" medium="image" fileSize="468867">
        <media:title type="plain">Artery and plaque</media:title>
      </media:content>
    </item>
    <item>
      <title>Urotronic gets FDA nod for Optilume for male urethral stricture</title>
      <description>
        <![CDATA[The FDA has granted approval to Urotronic Inc. for its Optilume urethral drug-coated balloon (DCB) for the treatment of male urethral strictures. The device inhibits new scar tissue growth that may form after endoscopic dilations via the controlled release of paclitaxel, an antiproliferative that inhibits scar tissue formation.]]>
      </description>
      <guid>http://www.bioworld.com/articles/514287</guid>
      <pubDate>Tue, 14 Dec 2021 13:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/514287-urotronic-gets-fda-nod-for-optilume-for-male-urethral-stricture</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2021/12-14-Urotronic-Optilume.webp?t=1639522081" type="image/png" medium="image" fileSize="175385">
        <media:title type="plain">12-14-Urotronic-Optilume.png</media:title>
        <media:description type="plain">Urotronic Inc.'s Optilume DCB</media:description>
      </media:content>
    </item>
    <item>
      <title>Medtronic’s Prevail DCB begins rollout in Europe</title>
      <description>
        <![CDATA[Medtronic plc launched the newest product in its coronary portfolio, the Prevail drug-coated balloon (DCB) catheter, in Europe following CE mark approval. The device is intended for use during minimally invasive procedures to open narrowed or clogged arteries in patients with coronary artery disease.]]>
      </description>
      <guid>http://www.bioworld.com/articles/509734</guid>
      <pubDate>Mon, 26 Jul 2021 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/509734-medtronics-prevail-dcb-begins-rollout-in-europe</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2020/8-25-Medtronic-HQ.webp?t=1627334034" type="image/png" medium="image" fileSize="2189430">
        <media:title type="plain">Medtronic's headquarters in Minneapolis</media:title>
        <media:description type="plain">Operational headquarters. Credit: Medtronic plc</media:description>
      </media:content>
    </item>
    <item>
      <title>New study of paclitaxel devices reverses narrative regarding mortality</title>
      <description>
        <![CDATA[The controversy over the use of paclitaxel in devices for the peripheral vasculature has taken a significant bite out of sales, but a new study serves to help reverse the narrative regarding mortality. According to a study of more than 168,000 Medicare patients, stents and angioplasty balloons coated with paclitaxel (PTX) were non-inferior to non-coated devices for mortality out to nearly three years, a finding that may encourage clinicians to return to normal utilization patterns and thus help to restore sales volumes.]]>
      </description>
      <guid>http://www.bioworld.com/articles/508253</guid>
      <pubDate>Tue, 15 Jun 2021 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/508253-new-study-of-paclitaxel-devices-reverses-narrative-regarding-mortality</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Devices/cardiovascular-stent-drug-eluting-device.webp?t=1623790472" type="image/png" medium="image" fileSize="1574468">
        <media:title type="plain">Illustration of stent angioplasty balloon in artery</media:title>
      </media:content>
    </item>
    <item>
      <title>Missing data, lack of operator blinding among issues that sidetrack Lutonix PMA</title>
      <description>
        <![CDATA[A U.S. FDA advisory committee voted 14 nays to three ayes that the benefits of the Lutonix 014 drug-coated balloon (DCB) do not outweigh the risks in a panel proceeding peppered by problems with missing data and a lack of operator blinding. The panel widely saw the use of paclitaxel-eluting technologies in other areas of the vasculature as a reassurance that this device might perform as promised, but the outcome nonetheless leaves the sponsor with a new round of negotiations with the FDA as to how to move forward.]]>
      </description>
      <guid>http://www.bioworld.com/articles/503731</guid>
      <pubDate>Wed, 17 Feb 2021 13:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/503731-missing-data-lack-of-operator-blinding-among-issues-that-sidetrack-lutonix-pma</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Regulatory/FDA-yellow-dice.webp?t=1626471222" type="image/png" medium="image" fileSize="416581">
        <media:title type="plain">Hand holding FDA blocks</media:title>
      </media:content>
    </item>
    <item>
      <title>Medtronic reports 9-month data from In.Pact BTK feasibility study</title>
      <description>
        <![CDATA[Medtronic plc reported promising results from a feasibility study of its In.Pact 0.014 drug-coated balloon (DCB) in critical limb ischemia (ICL) patients with chronic total occlusion (CTO) in the infrapopliteal arteries. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/499134</guid>
      <pubDate>Mon, 19 Oct 2020 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/499134-medtronic-reports-9-month-data-from-inpact-btk-feasibility-study</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cardiovascular/cardiovascular-legs-BTK.webp?t=1603146899" type="image/png" medium="image" fileSize="752101">
        <media:title type="plain">Illustration of vascular system in the legs</media:title>
      </media:content>
    </item>
    <item>
      <title>A sweet treat for Genesis Medtech as it acquires Chocolate Touch asset</title>
      <description>
        <![CDATA[HONG KONG &ndash; Singapore-based Genesis Medtech International Pte. Ltd. has acquired the Chocolate Touch drug-coated balloon angioplasty asset from Pleasanton, Calif.-based Trireme Medical LLC. The drug-device technology asset in question is designed with the intention of providing a safer and more effective treatment for patients suffering from peripheral vascular disease, compared to traditional balloon angioplasty.]]>
      </description>
      <guid>http://www.bioworld.com/articles/497512</guid>
      <pubDate>Tue, 08 Sep 2020 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/497512-a-sweet-treat-for-genesis-medtech-as-it-acquires-chocolate-touch-asset</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/puzzle-merge-addition.webp?t=1597785196" type="image/png" medium="image" fileSize="345848">
        <media:title type="plain">Hand adding piece to puzzle</media:title>
      </media:content>
    </item>
    <item>
      <title>Study shows benefits for dialysis patients with Medtronic DCB</title>
      <description>
        <![CDATA[Medtronic plc is highlighting the publication of primary endpoint results from the In.Pact AV Access trial in the <em>New England Journal of Medicine</em>. The study found that the company’s paclitaxel-coated balloon limits the number of reinterventions needed to maintain blood flow in patients with end-stage renal disease who have arteriovenous fistulae.]]>
      </description>
      <guid>http://www.bioworld.com/articles/496868</guid>
      <pubDate>Thu, 20 Aug 2020 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/496868-study-shows-benefits-for-dialysis-patients-with-medtronic-dcb</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2019/Medtronic-inpact-av-11-21.webp?t=1597957674" type="image/png" medium="image" fileSize="974410">
        <media:title type="plain">Illustration of In.Pact AV in vessels</media:title>
        <media:description type="plain">In.Pact AV drug-coated balloon. Credit: Medtronic plc</media:description>
      </media:content>
    </item>
    <item>
      <title>Cook prods FDA on balloon fatigue testing in catheter 510(k) draft guidance</title>
      <description>
        <![CDATA[Balloon catheters are in abundant use across the human vasculature. Thus, the January U.S. FDA draft guidance for angioplasty and specialty catheters captured a range of critical devices. However, Stephen Ferguson, of Bloomington, Ind.-based Cook Group Inc., cited several problems he saw with the draft, including that one of the specifications for balloon fatigue testing exceeds the level spelled out in an international standard adopted by the FDA.]]>
      </description>
      <guid>http://www.bioworld.com/articles/433704</guid>
      <pubDate>Fri, 13 Mar 2020 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/433704-cook-prods-fda-on-balloon-fatigue-testing-in-catheter-510k-draft-guidance</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2020/3-13-cook-medical-HQ.webp?t=1584131443" type="image/png" medium="image" fileSize="1707716">
        <media:title type="plain">3-13-cook-medical-HQ.png</media:title>
        <media:description type="plain">Cook headquarters. Credit: Cook Group</media:description>
      </media:content>
    </item>
    <item>
      <title>Study of paclitaxel devices in infrapopliteal arteries resurrects mortality controversy</title>
      <description>
        <![CDATA[The controversy over the use of paclitaxel-bearing devices in the femoropopliteal arteries is far from over. Now, a new medical journal article makes a similar claim about mortality in connection with the use of these devices in the infrapopliteal arteries, threatening once again to take a bite out of utilization. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/432600</guid>
      <pubDate>Thu, 23 Jan 2020 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/432600-study-of-paclitaxel-devices-in-infrapopliteal-arteries-resurrects-mortality-controversy</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cardiovascular/PAD-artery-plaque.webp?t=1588379965" type="image/png" medium="image" fileSize="468867">
        <media:title type="plain">Artery and plaque</media:title>
      </media:content>
    </item>
    <item>
      <title>Meta-analysis lends little support to paclitaxel mortality theory</title>
      <description>
        <![CDATA[The controversy over paclitaxel (PCT)-associated mortality in devices for the peripheral arteries is far from over, but another medical journal article has punched a hole in the credibility of the paclitaxel theory with the conclusion that the evidence is unequivocal and may be unpersuasive to physicians.]]>
      </description>
      <guid>http://www.bioworld.com/articles/432144</guid>
      <pubDate>Thu, 02 Jan 2020 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/432144-meta-analysis-lends-little-support-to-paclitaxel-mortality-theory</link>
    </item>
    <item>
      <title>Surmodics scores breakthrough device designation for Sundance SCB catheter</title>
      <description>
        <![CDATA[Surmodics Inc., of Eden Prairie, Minn., said the U.S. FDA has granted a breakthrough device designation to its Sundance sirolimus-coated balloon (SCB) catheter to potentially help those suffering from critical limb ischemia (CLI) and infrapopliteal arterial disease.]]>
      </description>
      <guid>http://www.bioworld.com/articles/430752</guid>
      <pubDate>Wed, 30 Oct 2019 00:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/430752-surmodics-scores-breakthrough-device-designation-for-sundance-scb-catheter</link>
    </item>
    <item>
      <title>Analysis appears to take some of the heat off paclitaxel-eluting stents, DCBs</title>
      <description>
        <![CDATA[LONDON – There is no evidence for increased mortality in patients receiving paclitaxel-eluting stents and drug-coated balloons (DCBs) to treat peripheral arterial disease, according to the largest real-world safety analysis to date. The findings may come as a relief to many, particularly after a meta-analysis published in December 2018 led to safety warnings and restrictions on the use of coated and drug-eluting devices.]]>
      </description>
      <guid>http://www.bioworld.com/articles/430441</guid>
      <pubDate>Thu, 10 Oct 2019 00:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/430441-analysis-appears-to-take-some-of-the-heat-off-paclitaxel-eluting-stents-dcbs</link>
    </item>
  </channel>
</rss>
